-
公开(公告)号：US20190322752A1
公开(公告)日：2019-10-24
申请号：US16352703
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Blanka Prinz
IPC: C07K16/28 , A61K39/395 , A61P35/00
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US20190135925A1
公开(公告)日：2019-05-09
申请号：US16091350
申请日：2017-03-17
Applicant: Cancer Research Technology Limited
Inventor： Sergio Quezada , Karl Peggs , Fred Vargas
Abstract: The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyR11b (CD32b).
-
公开(公告)号：US20180064793A1
公开(公告)日：2018-03-08
申请号：US15569334
申请日：2016-04-27
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Nicholas Mcgranahan , Rachel Rosenthal , Charles Swanton , Karl Peggs , Sergio Quezada
IPC: A61K39/00 , C12Q1/68 , C12N5/0783 , G01N33/574 , G01N33/50
CPC classification number: A61K39/0011 , C12N5/0636 , C12N2501/505 , C12N2502/99 , C12Q1/6886 , C12Q2600/156 , G01N33/505 , G01N33/57423 , G01N33/5743
Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
-
公开(公告)号：US20240309101A1
公开(公告)日：2024-09-19
申请号：US18470875
申请日：2023-09-20
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C12N15/85
CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US11879014B2
公开(公告)日：2024-01-23
申请号：US16494962
申请日：2018-03-03
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
CPC classification number: C07K16/2866 , C07K14/55 , C07K16/2818 , A61K39/0011 , A61K45/06 , C07K2317/31 , C07K2317/52 , C07K2317/60 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
-
Patent Agency Ranking
公开(公告)号：US11851494B2
公开(公告)日：2023-12-26
申请号：US16979931
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Sergio Quezada
IPC: C07K16/28 , A61P35/02 , C12N15/85 , A61P35/00 , A61K39/395 , C07K14/55 , A61K45/06 , A61K39/00 , C07K14/05
CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US11814434B2
公开(公告)日：2023-11-14
申请号：US16979930
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , James Geoghegan , Bianka Prinz , Sergio Quezada
CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US11098121B2
公开(公告)日：2021-08-24
申请号：US15758165
申请日：2016-09-12
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Nicholas McGranahan , Rachel Rosenthal , Charles Swanton , Karl Peggs , Sergio Quezada
IPC: A61K39/395 , G16B30/00 , C07K16/28 , G16B40/00 , G01N33/574
Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.
-
公开(公告)号：US20210009703A1
公开(公告)日：2021-01-14
申请号：US16979930
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , James Geoghegan , Bianka Prinz , Sergio Quezada
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US10752691B2
公开(公告)日：2020-08-25
申请号：US16352709
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.019 seconds)
